Hi,<div><br></div><div>I know that some of you are on Azithromycin.</div><div><br></div><div>There was a recent study on inhaled Azithromycin, which was reported in the 2011 cystic fibrosis conference in Hamburg, germany.</div><div><br></div><div>I wonder if anyone out there has tried that or talked to the doctor about it.</div><div><br></div><div>the researched used eFlow and <span class="Apple-style-span" style="color: rgb(0, 0, 0); font-family: verdana, arial, sans-serif; font-size: 13px; line-height: 19px; background-color: rgb(255, 255, 255); ">(100 mg/mL) aqueous azithromycin inhalation solution</div><div><br></div><div>the short version of the study is below:</div><div><br></div><div><span class="Apple-style-span" style="color: rgb(0, 0, 0); font-family: verdana, arial, sans-serif; font-size: 13px; line-height: 19px; background-color: rgb(255, 255, 255); ">Medical rationale for nebulisation of a novel high-concentration<br>(100 mg/mL) aqueous azithromycin inhalation solution<br>M. Keller1, J.M. Schierholz1, U. Schuschnig1, O. Denk1, M. Knoch1. 1PARI<br>Pharma GmbH, Aerosol Research Insitute, Graefelfing, Germany<br>Objective: In addition to its antibiotic activity, Azithromycin (AZM) has antiinflammatory, immunomodulatory and mucus regulating effects. Since oral bioavailability is only about 37%, inhalation can provide high local doses in the airways<br>as the target site to treat CF and bronchiectasis (BE). Topical use of aerosolized<br>azithromycin may increase mucociliary clearance, decrease mucus hypersecretion<br>and reduce IL8, neutrophils, rhinovirus replication, pro-inflammatory proteins, nasal<br>polyps, and protect ciliated epithelium against oxidative damage. Hence, based on<br>such literature data local effects of AZM may improve therapeutic efficacy over oral<br>or i.v. application reducing at the same adverse side effects and resistance formation<br>as known from other inhaled antibiotics.<br>Results: Drug delivery efficiency of a novel taste masked AZM solution<br>(100 mg/mL) utilizing a customised eFlow electronic nebuliser was assessed by<br>breath simulation tests carried out in triplicate, each. In-vitro delivered doses<br>(DDs) of ~75% and respirable dose (RD) of ~50% suggest that a lung deposition<br>of about 40% can be expected. Inhalation tests confirmed good tolerability and<br>acceptable taste.<br>Conclusion: Targeted aerosolized AZM therapy by nebulisation via eFlow technology<br>platform devices may be more advantageous and effective compared to<br>oral application. Hence, the proposed targeted delivery concept of a novel AZM<br>inhalation formulation may open new perspectives for the treatment of CF and BE<br>as well as severe neutrophilic asthma, COPD and mycobacterium avium complex<br>induced infections. Thus, clinical studies are warranted to evaluate the therapeutic<br>value of inhaled Azithromycin.</div>
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
inhaled Azithromycin
- Thread starter markbrave
- Start date
Hi,<br>I know that some of you are onAzithromycin.<br>There was a recent study on inhaledAzithromycin, which was reported in the 2011 cystic fibrosis conference in Hamburg, germany.<br>I wonder if anyone out there has tried that or talked to the doctor about it.<br>the researched used eFlow and<span class="Apple-style-span" style="color: rgb(0, 0, 0); font-family: verdana, arial, sans-serif; font-size: 13px; line-height: 19px; background-color: rgb(255, 255, 255); ">(100 mg/mL) aqueous azithromycin inhalation solution<br>the short version of the study is below:<br><span class="Apple-style-span" style="color: rgb(0, 0, 0); font-family: verdana, arial, sans-serif; font-size: 13px; line-height: 19px; background-color: rgb(255, 255, 255); ">Medical rationale for nebulisation of a novel high-concentration<br>(100 mg/mL) aqueous azithromycin inhalation solution<br>M. Keller1, J.M. Schierholz1, U. Schuschnig1, O. Denk1, M. Knoch1. 1PARI<br>Pharma GmbH, Aerosol Research Insitute, Graefelfing, Germany<br>Objective: In addition to its antibiotic activity, Azithromycin (AZM) has antiinflammatory,immunomodulatory and mucus regulating effects. Since oral bioavailabilityis only about 37%, inhalation can provide high local doses in the airways<br>as the target site to treat CF and bronchiectasis (BE). Topical use of aerosolized<br>azithromycin may increase mucociliary clearance, decrease mucus hypersecretion<br>and reduce IL8, neutrophils, rhinovirus replication, pro-inflammatory proteins, nasal<br>polyps, and protect ciliated epithelium against oxidative damage. Hence, based on<br>such literature data local effects of AZM may improve therapeutic efficacy over oral<br>or i.v. application reducing at the same adverse side effects and resistance formation<br>as known from other inhaled antibiotics.<br>Results: Drug delivery efficiency of a novel taste masked AZM solution<br>(100 mg/mL) utilizing a customised eFlow electronic nebuliser was assessed by<br>breath simulation tests carried out in triplicate, each. In-vitro delivered doses<br>(DDs) of ~75% and respirable dose (RD) of ~50% suggest that a lung deposition<br>of about 40% can be expected. Inhalation tests confirmed good tolerability and<br>acceptable taste.<br>Conclusion: Targeted aerosolized AZM therapy by nebulisation via eFlow technology<br>platform devices may be more advantageous and effective compared to<br>oral application. Hence, the proposed targeted delivery concept of a novel AZM<br>inhalation formulation may open new perspectives for the treatment of CF and BE<br>as well as severe neutrophilic asthma, COPD and mycobacterium avium complex<br>induced infections. Thus, clinical studies are warranted to evaluate the therapeutic<br>value of inhaled Azithromycin.
Hi,<br>I know that some of you are onAzithromycin.<br>There was a recent study on inhaledAzithromycin, which was reported in the 2011 cystic fibrosis conference in Hamburg, germany.<br>I wonder if anyone out there has tried that or talked to the doctor about it.<br>the researched used eFlow and<span class="Apple-style-span" style="color: rgb(0, 0, 0); font-family: verdana, arial, sans-serif; font-size: 13px; line-height: 19px; background-color: rgb(255, 255, 255); ">(100 mg/mL) aqueous azithromycin inhalation solution<br>the short version of the study is below:<br><span class="Apple-style-span" style="color: rgb(0, 0, 0); font-family: verdana, arial, sans-serif; font-size: 13px; line-height: 19px; background-color: rgb(255, 255, 255); ">Medical rationale for nebulisation of a novel high-concentration<br>(100 mg/mL) aqueous azithromycin inhalation solution<br>M. Keller1, J.M. Schierholz1, U. Schuschnig1, O. Denk1, M. Knoch1. 1PARI<br>Pharma GmbH, Aerosol Research Insitute, Graefelfing, Germany<br>Objective: In addition to its antibiotic activity, Azithromycin (AZM) has antiinflammatory,immunomodulatory and mucus regulating effects. Since oral bioavailabilityis only about 37%, inhalation can provide high local doses in the airways<br>as the target site to treat CF and bronchiectasis (BE). Topical use of aerosolized<br>azithromycin may increase mucociliary clearance, decrease mucus hypersecretion<br>and reduce IL8, neutrophils, rhinovirus replication, pro-inflammatory proteins, nasal<br>polyps, and protect ciliated epithelium against oxidative damage. Hence, based on<br>such literature data local effects of AZM may improve therapeutic efficacy over oral<br>or i.v. application reducing at the same adverse side effects and resistance formation<br>as known from other inhaled antibiotics.<br>Results: Drug delivery efficiency of a novel taste masked AZM solution<br>(100 mg/mL) utilizing a customised eFlow electronic nebuliser was assessed by<br>breath simulation tests carried out in triplicate, each. In-vitro delivered doses<br>(DDs) of ~75% and respirable dose (RD) of ~50% suggest that a lung deposition<br>of about 40% can be expected. Inhalation tests confirmed good tolerability and<br>acceptable taste.<br>Conclusion: Targeted aerosolized AZM therapy by nebulisation via eFlow technology<br>platform devices may be more advantageous and effective compared to<br>oral application. Hence, the proposed targeted delivery concept of a novel AZM<br>inhalation formulation may open new perspectives for the treatment of CF and BE<br>as well as severe neutrophilic asthma, COPD and mycobacterium avium complex<br>induced infections. Thus, clinical studies are warranted to evaluate the therapeutic<br>value of inhaled Azithromycin.